Stridebio, Inc.

Also on record

Records under this name other than patents Stridebio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 7 of 7 · Back to Stridebio, Inc.

Patent	Title	Status	Expires	Confidence
US 11,976,096	Antibody-evading virus vectors Formerly held In force Ends no later than Apr 3, 2039 · From the USPTO record	In force	Ends no later than Apr 3, 2039	From the USPTO record
US 12,060,390	Antibody-Evading Virus Vectors Formerly held In force Term ends Apr 3, 2039 · High confidence	In force	Term ends Apr 3, 2039	High confidence
US 11,981,914	Recombinant adeno-associated virus vectors Formerly held In force Term ends Mar 20, 2040 · From the USPTO record	In force	Term ends Mar 20, 2040	From the USPTO record
US 12,116,384	Virus Vectors for Targeting Ophthalmic Tissues Formerly held In force Term ends Mar 28, 2041 · High confidence	In force	Term ends Mar 28, 2041	High confidence
US 12,091,435	Antibody-Evading Virus Vectors Formerly held In force Term ends Jul 19, 2041 · High confidence	In force	Term ends Jul 19, 2041	High confidence
US 12,104,163	Adeno-Associated Virus Vectors for Treatment of Rett Syndrome Formerly held In force Ends no later than Nov 24, 2041 · Medium confidence	In force	Ends no later than Nov 24, 2041	Medium confidence
US 11,905,523	Adeno-Associated Viral Vectors for Treatment of Niemann-Pick Disease Type-C Formerly held In force Ends no later than Dec 17, 2041 · Medium confidence	In force	Ends no later than Dec 17, 2041	Medium confidence